# Phamacokinetics and Safety Profiles of DA-1229_01 5/1000mg in Healthy Subjects at Fed State

> **NCT05739916** · PHASE1 · UNKNOWN · sponsor: **Dong-A ST Co., Ltd.** · enrollment: 34 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** DA-1229_01 5/1000mg (Before)
- **DRUG:** DA-1229_01 5/1000mg (After)

## Key facts

- **NCT ID:** NCT05739916
- **Lead sponsor:** Dong-A ST Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-30
- **Primary completion:** 2023-04-28
- **Final completion:** 2023-04-28
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2023-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05739916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05739916, "Phamacokinetics and Safety Profiles of DA-1229_01 5/1000mg in Healthy Subjects at Fed State". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05739916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*